Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | HTR7 | P34969 | 3/20 | 0.58 |
| ▸ | SCD | O00767 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85231 | 0.89 | HTR2A (0.58) | HTR2ADRD3HTR7DRD2KCNH2 | |
| SCHEMBL84574 | 0.87 | DRD2 (0.60) | HTR2ADRD3HTR7SCDDRD2 | |
| SCHEMBL85045 | 0.86 | HTR2A (0.52) | HTR2ADRD3HTR7DRD2KCNH2 | |
| SCHEMBL85223 | 0.85 | DRD2 (0.55) | HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL84998 | 0.84 | HTR2A (0.48) | HTR2ADRD3HTR7DRD2KCNH2 | |
| SCHEMBL84565 | 0.83 | HTR2A (0.61) | HTR2ADRD3HTR7DRD2KCNH2 | |
| SCHEMBL8853747 | 0.82 | HTR2A (0.64) | HTR2ADRD3HTR7SCDDRD2 | |
| SCHEMBL2733199 | 0.81 | HTR2A (0.55) | HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL10637192 | 0.79 | HTT (0.61) | HTR2ADRD3HTR7SCDHTT | |
| Fumaric Acid SCHEMBL1545387 | 0.79 | HTR2A (0.60) | HTR2ADRD3HTR7DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | HTR2A 284/4885DRD3 994/4885HTR7 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.